System: You are provided with a paragraph. Your goal is to automatically identify the most relevant tasks based on the content of the paragraph and generate an example of entailment (if the task conclusion can be logically inferred from the paragraph) and a different example of non-entailment (if it is unclear or the opposite conclusion is true). 

Step 1: Read the paragraph carefully. 
Step 2: Automatically decide which tasks are relevant based on the paragraph’s content. Relevant tasks may include, but are not limited to: 
    - Topic Classification 
    - Risk Classification
    - Sentiment Classification 
    - Tone Classification
    - Event Detection 
    - Entity Recognition 
    - Geographical Recognition 
    - Trend Detection 
    - Intent Detection 
    - Sector Identification 
    - Impact Classification 
    - Tense Identification (Past, Present, Future) 
    - Uncertainty Identification 

Step 3: For each relevant task you identify, generate two clear and concise examples whose labels match common practices for the task at hand: one for entailment and one for non-entailment. The example should speak about the text at the 3rd person. 
Step 4: Output the results in the following JSON format:

{
    'relevant_tasks': [
        {
            'task': <The automatically selected relevant task>,
            'examples': [
                {
                    'input': <The entailment example based on the paragraph>,
                    'label': 'entailment',
                },
                {
                    'input': <The non-entailment example (neutral or contradiction) based on the paragraph>,
                    'label': 'non-entailment',
                }
            ]
        },
        ...
    ]
}
User: The United Kingdom’s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our common shares. Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the EU, the United Kingdom, or the UK, was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK and the EU have signed a EU-UK Trade and Cooperation Agreement, or TCA, which became provisionally applicable on January 1, 2021 and entered into force on May 1, 2021. This agreement provides details on how some aspects of the UK and EU’s relationship will operate going forwards however there are still many uncertainties. The TCA primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Although the body of the TCA includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the TCA. The Annex provides a framework for the recognition of Good Manufacturing Practice, or GMP, inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that have occurred are that Great Britain (England, Scotland and Wales) is treated as a “third country,” a country that is not a member of the EU and whose citizens do not enjoy the EU right to free movement. Northern Ireland continues to follow many aspects of the EU regulatory rules, particularly in relation to trade in goods. As part of the TCA, the EU and the UK recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As it relates to marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland continues, however, to be covered by the marketing authorizations granted by the European Commission. For example, the scope of a marketing authorization for a medicinal product granted by the European Commission or by the competent authorities of EU Member States will no longer encompass Great Britain (England, Scotland and Wales). In these circumstances, a separate marketing authorization granted by the UK competent authorities is required to place medicinal products on the market in Great Britain. Northern Ireland continues, however, to be covered by the marketing authorizations granted by the European Commission.
Assistant: